Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253886209> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4253886209 endingPage "138" @default.
- W4253886209 startingPage "136" @default.
- W4253886209 abstract "Food Safety Commission of Japan (FSCJ) conducted a risk assessment of dicycranil (CAS No. 112636-83-6), a pyrimidine-derived insect growth regulator, using the evaluation reports from the Joint FAO/WHO Expert Committee on Food Additives (JECFA), the European Medicines Agency (EMEA), and also the Australian government. In an 18-month chronic toxicity/carcinogenicity study in mice, increased incidences of hepatocellular adenomas and carcinomas were observed in females in the 500 ppm group. In spite of a recent experiment implying the possible indirect genotoxicity of dicyclanil on the carcinogenicity, dicyclanil is unlikely to exert the carcinogenicity in vivo through the genotoxic mechanism judging from other studies. FSCJ recognized it as feasible to set the threshold value. Adverse effects detected at the lowest dose in various toxicological studies were the increased plasma levels of cholesterol and phospholipid at 100 ppm (equivalent to 2.7 mg/kg bw/day in males and 3.5 mg/kg bw/day in females) in a 90-day subacute toxicity study in dogs. No-observed-adverse-effect level (NOAEL) of this study was 20 ppm (equivalent to 0.61 mg/kg bw/day in males and 0.71 mg/kg bw/day in females). On the other hand, the NOAEL in a long term study, a 12-month chronic toxicity study in dogs was 25 ppm (equivalent to 0.71 mg/kg bw/day in males) based on increased level of plasma cholesterol observed only in males at 150 ppm (equivalent to 4.4 mg/kg bw/day in males and 5.1 mg/kg bw/day in females). The increased cholesterol levels in plasma were common in both studies in dogs. It was appropriate to choose the NOAEL for the effect on cholesterol in the longer term treatment, and thus FSCJ adopted the NOAEL of 0.71 mg/kg bw/day. Consequently, FSCJ specified the ADI of 0.0071 mg/kg bw/day for dicyclanil based on the NOAEL of 0.71 mg/kg bw/day in the 12-month chronic toxicity study in dogs, by applying a safety factor of 100." @default.
- W4253886209 created "2022-05-12" @default.
- W4253886209 date "2018-01-01" @default.
- W4253886209 modified "2023-09-30" @default.
- W4253886209 title "Dicyclanil (Veterinary Medicinal Products)" @default.
- W4253886209 doi "https://doi.org/10.14252/foodsafetyfscj.2018007s" @default.
- W4253886209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32038901" @default.
- W4253886209 hasPublicationYear "2018" @default.
- W4253886209 type Work @default.
- W4253886209 citedByCount "0" @default.
- W4253886209 crossrefType "journal-article" @default.
- W4253886209 hasBestOaLocation W42538862091 @default.
- W4253886209 hasConcept C114246631 @default.
- W4253886209 hasConcept C12174686 @default.
- W4253886209 hasConcept C126322002 @default.
- W4253886209 hasConcept C140793950 @default.
- W4253886209 hasConcept C161176658 @default.
- W4253886209 hasConcept C175961577 @default.
- W4253886209 hasConcept C197934379 @default.
- W4253886209 hasConcept C2777495288 @default.
- W4253886209 hasConcept C2778959862 @default.
- W4253886209 hasConcept C29730261 @default.
- W4253886209 hasConcept C33070731 @default.
- W4253886209 hasConcept C38652104 @default.
- W4253886209 hasConcept C41008148 @default.
- W4253886209 hasConcept C51671895 @default.
- W4253886209 hasConcept C53164099 @default.
- W4253886209 hasConcept C55493867 @default.
- W4253886209 hasConcept C6557445 @default.
- W4253886209 hasConcept C71924100 @default.
- W4253886209 hasConcept C86803240 @default.
- W4253886209 hasConcept C98274493 @default.
- W4253886209 hasConceptScore W4253886209C114246631 @default.
- W4253886209 hasConceptScore W4253886209C12174686 @default.
- W4253886209 hasConceptScore W4253886209C126322002 @default.
- W4253886209 hasConceptScore W4253886209C140793950 @default.
- W4253886209 hasConceptScore W4253886209C161176658 @default.
- W4253886209 hasConceptScore W4253886209C175961577 @default.
- W4253886209 hasConceptScore W4253886209C197934379 @default.
- W4253886209 hasConceptScore W4253886209C2777495288 @default.
- W4253886209 hasConceptScore W4253886209C2778959862 @default.
- W4253886209 hasConceptScore W4253886209C29730261 @default.
- W4253886209 hasConceptScore W4253886209C33070731 @default.
- W4253886209 hasConceptScore W4253886209C38652104 @default.
- W4253886209 hasConceptScore W4253886209C41008148 @default.
- W4253886209 hasConceptScore W4253886209C51671895 @default.
- W4253886209 hasConceptScore W4253886209C53164099 @default.
- W4253886209 hasConceptScore W4253886209C55493867 @default.
- W4253886209 hasConceptScore W4253886209C6557445 @default.
- W4253886209 hasConceptScore W4253886209C71924100 @default.
- W4253886209 hasConceptScore W4253886209C86803240 @default.
- W4253886209 hasConceptScore W4253886209C98274493 @default.
- W4253886209 hasIssue "3" @default.
- W4253886209 hasLocation W42538862091 @default.
- W4253886209 hasLocation W42538862092 @default.
- W4253886209 hasLocation W42538862093 @default.
- W4253886209 hasLocation W42538862094 @default.
- W4253886209 hasOpenAccess W4253886209 @default.
- W4253886209 hasPrimaryLocation W42538862091 @default.
- W4253886209 hasRelatedWork W1994136014 @default.
- W4253886209 hasRelatedWork W2000270626 @default.
- W4253886209 hasRelatedWork W2043174331 @default.
- W4253886209 hasRelatedWork W2054169229 @default.
- W4253886209 hasRelatedWork W2091119776 @default.
- W4253886209 hasRelatedWork W228363992 @default.
- W4253886209 hasRelatedWork W2754569041 @default.
- W4253886209 hasRelatedWork W2794249401 @default.
- W4253886209 hasRelatedWork W2915272261 @default.
- W4253886209 hasRelatedWork W4246914779 @default.
- W4253886209 hasVolume "6" @default.
- W4253886209 isParatext "false" @default.
- W4253886209 isRetracted "false" @default.
- W4253886209 workType "article" @default.